NM 504

Drug Profile

NM 504

Alternative Names: Cobiotic formulation - MicroBiome Therapeutics; NM-504; NM-504 cobiotic

Latest Information Update: 24 Feb 2016

Price : $50

At a glance

  • Originator MicroBiome Therapeutics
  • Class Antihyperglycaemics
  • Mechanism of Action Metagenome modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Prediabetic-state
  • Phase 0 Type 2 diabetes mellitus

Most Recent Events

  • 24 Feb 2016 Phase-II development for Prediabetic state is ongoing in USA
  • 08 Apr 2015 MicroBiome Therapeutics receives patent allowance for NM 504 in USA
  • 01 Jul 2014 NuMe Health completes a phase 0 trial in Type-2 diabetes mellitus (Adjunctive treatment) in USA (NCT01866462)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top